Interferon α bei Patienten mit chronischer Hepatitis C

Baranyi, Andreas; Meinitzer, Andreas; Stepan, Alexandra; Matejka, J.; Stauber, Rudolf; Hp, Kapfhammer; Rothenhäusler, Hans-Bernd

doi:10.1007/s00115-011-3302-y

Cited by 6 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 11 Małyszczak et al and Baranyi et al found that 3 months after the first IFN-α administration, HQOL had significantly decreased in multiple domains. 12 , 13 Pojoga et al observed that the antiviral therapy does not affect the HQOL of HCV patients who have a markedly reduced HQOL both before and after treatment. 14 On the other hand, Hunt et al found neither a reduced HQOL in HCV patients compared with the general US population nor a change during IFN-α therapy.…”

Section: Introductionmentioning

confidence: 99%

Interferon α Therapy in Patients with Chronic Hepatitis C Infection: Quality of Life and Depression

et al. 2015

View full text Add to dashboard Cite

Health-related quality of life was examined in 49 patients with hepatitis C virus with no psychiatric history who received interferon (IFN)-α treatment. Quality of life was assessed at baseline, at 3-time points during IFN-α therapy and at 1-6 month follow-up, using SF-36. Hepatitis C virus patients showed poorer physical functioning and better social and mental functioning than a normal population. Significant decreases from baseline SF-36 scores were observed at an early phase of treatment. Six patients developed major depression during IFN-α treatment. At baseline, they had reported more bodily pain than patients who did not develop depression during treatment. Planned contrasts revealed that worsening in some dimensions of quality of life at 2 months was greater in depressed than in non-depressed patients. Results suggest that depressive symptoms should be accurately monitored during IFN-α therapy even in patients with no psychiatric history, especially if they present with bodily pain.

show abstract

Section: Introductionmentioning

confidence: 99%

Interferon α Therapy in Patients with Chronic Hepatitis C Infection: Quality of Life and Depression

et al. 2015

View full text Add to dashboard Cite

show abstract

“…A recent study of patients with chronic HCV (Baranyi, Meinitzer, Stepan, Matejka, Stauber, Kapfhammer, et al, 2011) confirmed that after the first 3 months of therapy with interferon there is a significant reduction in physical Hypochondriasis (range 0-9) Disease conviction (range 0-6) Psychological versus somatic perception (range 0-5) Affective inhibition (range 0-5) Dysphoria (range 0-5) Denial (range 0-5) Irritability (range 0-6) BDI score p.18…”

Section: Discussionmentioning

confidence: 91%

Depression and Behavioral Disorders in Chronic Viral Hepatitis

Micali

Squadrito

Raimondo

et al. 2013

Illness, Crisis & Loss

View full text Add to dashboard Cite

This study assesses behavioral disorders and depression in 50 patients with chronic viral hepatitis (32 patients with HBV and 18 patients with HCV). A psychodiagnostic protocol composed of the IBQ and the BDI was administered to the entire sample in two stages-at the time of recruitment (T1) and after 8 months, when patients were receiving pharmacological treatment (T2). The results showed a predominance of behavioral disorders and depression in patients with HCV compared to HBV patients, although all patients with chronic viral hepatitis, despite reduction in viral load, displayed reduced quality of working life and relationships.

show abstract

Hepatitis C und ihre Auswirkungen auf das Gehirn

Peters

Wehking

2012

Trauma Berufskrankh

View full text Add to dashboard Cite

Interferon α bei Patienten mit chronischer Hepatitis C

Cited by 6 publications

References 24 publications

Interferon α Therapy in Patients with Chronic Hepatitis C Infection: Quality of Life and Depression

Interferon α Therapy in Patients with Chronic Hepatitis C Infection: Quality of Life and Depression

Depression and Behavioral Disorders in Chronic Viral Hepatitis

Hepatitis C und ihre Auswirkungen auf das Gehirn

Contact Info

Product

Resources

About